Filing Flows › IGC Pharma (IGC) › Q2 2026
IGC Pharma (IGC) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 14, 2026
IGC Pharma (IGC) reported revenue of $265K for the second quarter 2026 (Q2 2026), -19% from a year earlier and -16% from the quarter before.
IGC Pharma, Q2 2026: revenue $265K (-19% year over year), net loss $2.9M, operating cash flow −$1.4M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $265K | -16% | -19% |
| Operating profit | −$2.8M | — | — |
| Net earnings | −$2.9M | — | — |
| Operating cash flow | −$1.4M | — | — |
What changed
Revenue was $265K in Q2 2026, down 19% year over year and down 16% from the previous quarter. White Labeling Services was the largest line at 97% of revenue. White Labeling Services lost $66K year over year (down 20%), 105% of the total change.
Gross margin was 18.1%, down 28.8 points from Q2 2025. Operating costs exceeded revenue by $2.8M, an operating margin of -1050.6%. Operating expenses grew 38% against a revenue fall of 19%. The fastest-growing cost line was Research & development (+63%). The quarter ended with a net loss of $2.9M, wider than the previous quarter's $2.4M loss.
Operating cash flow was −$1.4M. Non-cash charges added back $56K of depreciation and amortization and $200K of share-based compensation. Working capital and other items added $1.3M. Capital expenditures of $5K exceeded it, leaving free cash flow of −$1.4M.
Questions
What was IGC Pharma's revenue in the second quarter 2026?
IGC Pharma (IGC) reported revenue of $265K for the second quarter 2026 (Q2 2026), -19% from a year earlier and -16% from the quarter before.
Source: IGC Pharma 10-Q on SEC EDGAR.